exocad releases PartialCAD for Partial Framework Design

Food and Healthcare Press Releases Wednesday April 11, 2018 14:50
DARMSTADT, Germany--11 Apr--PRNewswire/InfoQuest
exocad recently announced the commercial availability of its Partial Framework Design module.

exocad's PartialCAD provides unparalleled flexibility and design freedom thanks to its unique voxel-based technology. Tillmann Steinbrecher, CEO of exocad, says: "Our goal is that anything that can be made in wax, can also be designed with exocad. With this new module, even the most demanding experts in Removable Partial Dentures will find their design needs met."

Mr. Steinbrecher also points out that "the traditional process of creating partial frameworks is fully analog and both resource intensive and time consuming."   He says that "The PartialCAD module enables efficient production with 3d printers or milling machines, thus saving time and increasing productivity."

Partial Frameworks can be combined with crown and bridge designs, or other indications available in the exocad DentalCAD platform - e.g. for secondary structures on telescopic crowns, attachments, advanced implant cases, and more.

About exocad GmbH

exocad GmbH (exocad.com) is a dynamic and innovative software company committed to expanding the possibilities of digital dentistry and providing OEMs (Original Equipment Manufacturers) with flexible, reliable, and easy-to-use CAD/CAM software for dental labs and dental practices. exocad software has been chosen by leading OEMs worldwide for integration into their dental CAD/CAM offerings, and thousands of exocad DentalCAD licenses are sold each year. For more information and a list of exocad reseller partners, please visit exocad.com.

Photo - https://mma.prnewswire.com/media/665021/partial_framework_02.jpg

Latest Press Release

The Menarini Group Announces Meropenem/vaborbactam European Marketing Authorization

- Meropenem/vaborbactam approved on 20th November 2018 by the European Commission for clinical use in adult patients with difficult-to-treat infections - The first combination of a carbapenem and a beta-lactamase inhibitor approved for clinical use in...

Merck Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

- FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer - First regulatory designation for M7824 following recent presentation of first clinical data in BTC - BTC is a group of rare, aggressive...

Merck in Agreement With Cyclica for AI-augmented Screening Platform to Expand Research Capabilities

- Agreement to screen discovery and early development compounds using artificial intelligence and computational biophysics - Cloud-based in silico platform that screens small molecules to determine polypharmacological profiles - Evaluation to include...

Vitality-linked Insurers to Get 100 million People 20% More Active by 2025

Building on the results of the largest behaviour change study on physical activity, Vitality and its global network of insurers have collectively committed to improving the health of millions over the next seven years. This is in line with the World...

World Congress of Cardiology Cardiovascular Health 2018 Opens in Dubai

- Professor David Wood, President of the World Heart Federation, welcomes more than 5000 cardiologists, doctors, nurses, and health and policy experts from around the world to Dubai for WCC 2018 at a time when the opportunities for a sustainable impact...

Related Topics